Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo-Nordisk Norditropin launched Feb. 20; patent litigation with Genentech is ongoing.

Executive Summary

NOVO NORDITROPIN LAUNCH FEB. 20 FOR HUMAN GROWTH HORMONE INSUFFICIENCY brings the Novo Nordisk somatropin product to market without having settled underlying patent infringement issues. Norditropin was cleared by FDA in May 1995, but the launch has been delayed by patent litigation between Novo Nordisk and Genentech. The path to market was cleared for Novo when a D.C. appeals court granted a stay of a lower court's preliminary injunction against the Norditropin launch ("The Pink Sheet" Dec. 23, 1996, In Brief). Bio-Technology General's Bio-Tropin somatropin human growth hormone product is still held up by a preliminary injunction dating from April 1996 ("The Pink Sheet" April 15, 1996, T&G-3).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel